# Gedatolisib Combination Shows PFS Improvement in PIK3CA-Wild-Type HR+/HER2- Metastatic Breast Cancer

> clinical trial · REPORTED · 2026-07-31

Pivotal trial data for gedatolisib plus fulvestrant with or without palbociclib demonstrated improved progression-free survival and response rates in PIK3CA-wild-type hormone receptor-positive, HER2-negative metastatic breast cancer, targeting PI3K and mTORC1/2 to overcome endocrine resistance. This was highlighted as one of five key solid tumor advances of July 2026.

About Gedatolisib / Pfizer: Gedatolisib is a pan-class I PI3K and mTORC1/2 inhibitor in clinical development for HR+/HER2- metastatic breast cancer, being studied in combination with endocrine and CDK4/6 inhibitor therapies.

- Company: Gedatolisib / Pfizer
- Sector: oncology
- Primary source: https://www.pharmacytimes.com/view/five-solid-tumor-advances-that-defined-july-2026

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.